Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Hepatic Encephalopathy

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CBCT-Guided Pencil Beam Scanning Proton Therapy for Moving Lung Tumours: PROMO Study- Standardised Workflow and Early Outcomes From a Consecutive Real-World Cohort.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026

Same author

Financial Burden of General Surgeries by Insurance Status: A Single-Center Case Study from a Quaternary Care Teaching Hospital in Karnataka, India.

Healthcare (Basel, Switzerland)·2026

Same author

A Holistic Insight into the Caregivers of Patients with Multiple Myeloma: Burden and Opportunities for Interventions - A Scoping Review.

Indian journal of palliative care·2025

Same author

Development of multiplexed flow based assay for simultaneous identification and estimation of meningococcal capsular polysaccharide serogroups A, C, W, Y and X for conjugate vaccine manufacturing.

Journal of immunological methods·2025

Same author

Out-of-Pocket Expenditure (OOPE) on Selected Surgeries in the Obstetrics and Gynaecology Department incurred by Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), Private Health Insurance and Uninsured Patients in a Tertiary Care Teaching Hospital in Karnataka state of India.

F1000Research·2025

Same author

Unveiling the Heartbeat of Healing: Exploring Organizational Culture in a Tertiary Hospital's Emergency Medicine Department and Its Influence on Employee Behavior and Well-Being.

International journal of environmental research and public health·2024

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Nevirapine-induced fulminant hepatitis.

J K Maniar¹, S R Shah, Reena Verma

¹Department of Infectious Diseases, Jaslok Hospital and Research Centre, Mumbai, India.

The Journal of the Association of Physicians of India

|March 6, 2007

Summary

Nevirapine (NVP) can cause liver damage, but fatal outcomes are uncommon. This case highlights a rare fatal NVP-induced hepatitis, emphasizing vigilant monitoring for early detection and intervention.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jul 16, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Area of Science:

Hepatology
Pharmacology
Toxicology

Background:

Nevirapine (NVP) is an antiretroviral medication used in HIV treatment.
Hepatotoxicity is a known, albeit infrequent, adverse effect of NVP therapy.
Fatal outcomes from NVP-induced liver injury are exceptionally rare.

Observation:

A young patient developed fatal hepatitis following NVP administration.
The patient had no identifiable risk factors or preceding skin rash.
Pre-existing, undiagnosed chronic liver dysfunction may have exacerbated the NVP toxicity.

Findings:

This case represents a rare instance of fatal nevirapine-induced hepatitis.
The absence of typical risk factors underscores the unpredictable nature of NVP toxicity.
Underlying silent liver disease appears to be a critical factor in the fatal outcome.

Implications:

Clinicians must exercise caution when prescribing NVP, especially in patients with potential liver compromise.
Regular and thorough monitoring of liver function is crucial during NVP treatment.
Prompt drug withdrawal upon suspicion of hepatotoxicity is essential to prevent severe outcomes.